BTK and neoplasm: In CLL and B-cell non-Hodgkin’s lymphoma (NHL), SYK is involved both in Bruton’s Tyrosine Kinase (BTK) pathway activation and IL4-driven resistance to BTK inhibitors, while JAK kinases transduce cytokine signaling, which supports tumor growth.